Frequently Asked Questions (FAQs)

For Principal Investigators and Site Owners

At Research Management Partners (RMP), our model is built on clear role definition, full operational control, strict regulatory alignment, and complete transparency. The following questions and answers are intended to explain in detail how our SMO–MSO model works in practice for Principal Investigators (PIs) and site owners.

How does RMP execute its responsibilities with the PI and the site?

RMP executes its responsibilities through a centralized operational model with defined authorization, contractual control, and task allocation between RMP and the PI/site.

First, RMP obtains a signed consent from the Principal Investigator and the site owner. This authorizes RMP to represent the site, submit feasibility, and request studies on their behalf. RMP conducts feasibility, sponsor outreach, and study identification centrally. When a study opportunity becomes available, RMP notifies the PI/site before any final commitment is made. The PI/site then decides whether to accept or decline participation.

If the study is accepted, the site executes a study-specific agreement with RMP. From the moment of execution through study close-out, RMP assumes operational oversight, while the PI retains medical responsibility and protocol compliance oversight. RMP is responsible for regulatory coordination, including IRB submissions and essential documents, study start-up management, sponsor and CRO communication, study tracking, performance monitoring, quality oversight, and financial management such as budget negotiation, invoicing, collections, and payments. The PI/site remains responsible for patient recruitment and enrollment, conduct of protocol-required procedures, source documentation, data entry, subject safety, and clinical decision-making.

RMP negotiates the budget directly with the sponsor or CRO. The site is continuously informed during negotiations and has visibility into the budget structure. RMP incorporates its margin within sponsor negotiations without reducing site payments. RMP bills all procedures to the sponsor, collects payments, and disburses payments to the site per agreed terms. This removes administrative and financial burden from the site while maintaining full visibility. RMP’s model does not replace the regulatory responsibilities of the PI/site. Instead, it controls, supervises, and standardizes operations to reduce execution risk, while liability remains aligned with GCP and regulatory frameworks.

How does indemnification and liability work under the RMP model?

Indemnification terms are defined within each study agreement and sponsor contract. RMP operates as an operational and administrative entity, not as the medical decision-maker. The Principal Investigator retains responsibility for clinical oversight, as required under ICH-GCP.

As a condition to participate in any study, the PI and site must maintain active and up-to-date professional liability insurance and clinical trial coverage. This is verified by RMP prior to study award and continuously monitored. RMP’s role is to ensure all insurance and regulatory documentation is current and compliant with sponsor requirements before activation.

RMP reduces operational risk through pre-study validation of site readiness, including regulatory, staff, and infrastructure review, implementation of RMP SOPs aligned with sponsor and GCP requirements, on-site and remote oversight using EDC and RealTime systems, and internal review of study conduct prior to sponsor monitoring visits. Responsibilities for regulatory findings, audits, and adverse events are clearly defined across the SOP framework, protocol-specific requirements, and execution responsibility. The PI is ultimately responsible for patient safety, adverse event reporting, and overall study conduct and compliance per GCP. RMP ensures all processes are implemented correctly, followed in real time, and maintained in an audit-ready state through on-site evaluations and remote data and performance review. Regulatory findings, audits, and adverse events are managed and reported according to protocol, sponsor requirements, and SOPs, supervised operationally by RMP, but ultimately under PI responsibility as required by regulatory standards.

How does the financial structure work between the site and RMP?

RMP operates a transparent financial model aligned with industry standards while optimizing site cash flow and operational efficiency. RMP negotiates the full study budget directly with the sponsor or CRO. The site is informed at each step of the negotiation and has full visibility into the per-procedure budget. The site is paid based on its actual activity, meaning completed procedures, visits, and study work performed. RMP’s compensation is built into the sponsor-negotiated budget and is not deducted from site payments.

Start-up fees are negotiated with the sponsor and allocated to the site based on activation milestones. Coordinator and operational costs are the responsibility of the site, and RMP does not cover internal site costs. Pass-through expenses such as labs, imaging, and vendors are structured within the sponsor budget and tracked and billed by RMP according to protocol requirements.

RMP invoices the sponsor directly for all study activities and receives payments centrally. Once funds are received, payments are reconciled against actual site performance based on subjects, visits, and procedures completed. Disbursements are then made to the site accordingly and in alignment with earned revenue. This creates a centralized and controlled financial flow, eliminating billing burden from the site. The site has full visibility into the negotiated budget structure and clarity on what is paid per activity. RMP maintains tracking of all invoiced and collected amounts, alignment between sponsor payments and site disbursements, and a financial trail that is traceable and aligned with study performance, ensuring transparency at the operational level.

Who has authority over clinical and protocol-related decisions?

The Principal Investigator retains full authority over all clinical decisions, patient care, and protocol-related medical judgments. RMP does not intervene in medical decision-making. All activities are conducted in accordance with the study protocol and ICH-GCP under PI supervision.

RMP’s role is operational and supervisory, not clinical. RMP ensures that study activities are executed according to protocol, SOPs, and sponsor requirements, that processes are standardized and consistently followed across sites, and that the site’s operations are monitored and supported to ensure performance, compliance, and quality. RMP does not alter or override site operations. Both RMP SOPs and site SOPs are aligned with each other and with protocol requirements.

The PI and site staff are responsible for executing the study in accordance with protocol and SOPs. RMP monitors execution in real time, both on-site and remotely, ensures the correct flow of the study from start to close-out, and proactively identifies and addresses operational gaps. Any disagreement related to study conduct is resolved first by reference to the study protocol as the primary governing document, then by alignment with ICH-GCP and regulatory requirements, and then through application of agreed SOPs from both the site and RMP. The objective is always to maintain compliance, protect patient safety, and ensure protocol integrity. Final clinical authority remains with the Principal Investigator as required by regulation.

What are the standards for research personnel such as coordinators and staff?

RMP does not operate under minimum standards, only maximum standards. All personnel involved must have active and valid licenses corresponding to their role and responsibilities, as well as mandatory certifications including GCP and IATA when applicable for handling biological samples. For study coordinators, RMP requires a medical background as mandatory, such as Licensed Medical Assistant, Nurse, or equivalent clinical credential. RMP prioritizes personnel with clinical experience in research settings and the ability to operate under protocol-driven and regulatory-controlled environments.

Personnel are not imposed on the site. The site and PI maintain visibility of assigned personnel and operational alignment with their internal structure. Staff must meet both RMP standards and site and protocol requirements. The PI maintains full oversight of all delegated study activities and is responsible for ensuring staff perform according to protocol and GCP. RMP oversees training compliance, operational performance, and adherence to SOPs and protocol requirements, and continuously monitors staff performance on-site and through EDC and RealTime systems. Staff performance is operationally supervised by RMP and clinically overseen by the PI, as required by regulation.

Who owns the study data and how does RMP access it?

Data ownership remains with the sponsor and the site, as defined in the protocol and clinical trial agreement. RMP operates under authorized access via tripartite agreements among RMP, the site, and the sponsor. RMP has continuous access to study data through EDC, CTMS, and RealTime systems for operational oversight. RMP may also have access to site EMR systems, as authorized, strictly to support study execution and enable accurate billing and activity verification. This access is used to monitor, validate, and ensure real-time compliance, not to alter ownership.

RMP utilizes RealTime platforms integrated with CTMS and EDC systems to monitor study activities in real time, track patient visits, procedures, and data entry, and ensure protocol adherence across all sites. This gives RMP full operational visibility and control at the execution level and the ability to intervene operationally when deviations or delays are identified. All data access and handling are conducted under HIPAA-compliant frameworks and executed Business Associate Agreements where required. RMP ensures that Protected Health Information is accessed only for authorized study-related purposes and that all systems and workflows align with federal and sponsor-specific data protection requirements.

RMP operates within secure, sponsor-approved platforms including EDC, CTMS, and RealTime. Data security includes controlled user access, audit trails, activity logs, and role-based permissions. In the event of a breach, actions are taken according to HIPAA, sponsor requirements, and site and RMP SOPs. Systems are designed to ensure interoperability between EMR, CTMS, and EDC, and to maintain accurate and consistent data flow across platforms. RMP functions as a central operational oversight layer working alongside the site and the sponsor or CRO to ensure that all activities are executed according to protocol, regulatory compliance is maintained at all times, and data integrity and operational performance are consistently controlled.

How does RMP oversee adverse events, protocol deviations, IRB submissions, audits, and CAPA?

RMP operates as a central regulatory oversight layer, ensuring that all critical study activities are executed in full alignment with protocol, SOPs, and applicable regulations including ICH-GCP, FDA, and IRB requirements. The site is responsible for execution and initial documentation of adverse events and protocol deviations under PI supervision, as required by GCP. RMP monitors adverse events, serious adverse events, and protocol deviations in real time through EDC and RealTime platforms, verifies reporting timelines, protocol consistency, and data completeness and accuracy, and implements preventive and corrective controls when operational issues are identified. Sites with high deviation rates or repeated non-compliance are formally evaluated by RMP and may be removed from the network if standards are not met.

The site performs IRB submissions, continuing reviews, safety reporting, and amendments. RMP reviews, coordinates, and validates all submissions prior to filing, ensures alignment with protocol, sponsor, and regulatory requirements, ensures compliance with required timelines, and maintains centralized regulatory document control and tracking.

The Principal Investigator remains the ultimate regulatory authority during FDA inspections and audits, per GCP. RMP functions as the continuous oversight and audit-readiness management layer. RMP keeps all sites audit-ready at all times, conducts internal reviews prior to sponsor visits, and performs ongoing quality control assessments. During inspections and audits, RMP prepares and coordinates the site and ensures operational and documentation consistency. In case of findings, RMP leads, together with the site, root cause analysis and CAPA development and implementation, and follows through until full resolution and closure. All activities are governed by site SOPs, RMP SOPs aligned and implemented at the site level, and protocol-specific requirements. RMP ensures execution is standardized, controlled, and consistent across all sites. Operationally, the site executes, the PI is clinically responsible, and RMP supervises, controls, and ensures full regulatory compliance in real time.

Is the RMP model exclusive?

RMP’s SMO/MSO model is strictly non-exclusive by design. RMP does not believe in restrictive structures because forcing exclusivity creates friction, reduces performance, and ultimately leads to poor study outcomes. The model is built to support high-performing sites and investigators, not to constrain them.

Sites and Principal Investigators are free to work with any sponsor, CRO, or network outside of RMP and are under no exclusivity obligation at any level. RMP does not impose restrictions on a site’s broader research activity. However, once a study is accepted by the PI/site and a contract is executed, the site and PI are fully responsible for fulfilling that agreement through study completion. This includes executing the study according to protocol, maintaining performance and compliance, and ensuring a successful outcome with the sponsor. RMP operates under the same standard and commits fully from start-up through close-out.

RMP does not rely on restrictive non-circumvention clauses or post-termination limitations. The model is based on transparency, operational control, and performance-driven relationships. RMP works with professional investigators and sites who understand their responsibilities and are committed to delivering results. The operating principle is simple: RMP does not force participation, RMP does not restrict independence, but RMP does expect accountability once a commitment is made. In summary, there is no exclusivity, no restrictive clauses, full freedom to operate, and full responsibility once a study is accepted.

What happens if the relationship or a study is terminated?

Termination rights and notice periods are defined within each study-specific agreement. Each project is governed individually, and termination conditions are aligned with sponsor requirements and executed in full compliance with contractual obligations. Any termination must ensure proper study closure, regulatory compliance, and continuity of subject safety.

Active studies must continue under protocol and regulatory requirements until proper transition or close-out is completed. All data, regulatory documents, and study records are handled according to protocol, sponsor requirements, and applicable regulations including ICH-GCP, FDA, and IRB. RMP ensures full operational continuity during any transition and no disruption to study integrity or patient safety.

Financial reconciliation upon termination is handled with full transparency and traceability. Budgets are shared with site owners from day one as a mandatory practice. RMP invoices the sponsor directly, receives payments centrally, and disburses payments to the sites. Sites receive payments directly from RMP, while investigators are paid by the site, not by RMP. Reconciliation can be performed at any time upon request by the site or owners during the study and is conducted mandatorily by RMP at study close-out. Final payments are completed in full compliance with contractual terms and with total transparency. Operationally, termination is defined by contract, transition is controlled and compliant with no disruption, and financials are transparent, auditable, and reconciled at any time and mandatorily at close-out.

What is the overall operating philosophy of RMP?

At RMP, the model is built on clear role definition, full operational control, and strict regulatory alignment, while preserving complete clinical authority at the Principal Investigator level. RMP does not operate as a passive support entity. It functions as an embedded operational and oversight structure, ensuring that every study is executed in full compliance with protocol, SOPs, and ICH-GCP, with real-time supervision across all sites, and with complete financial and operational transparency. The framework is designed to standardize execution across sites, reduce variability and operational risk, maintain continuous audit readiness, and deliver predictable performance to sponsors. At the same time, sites remain non-exclusive and independent, PIs retain full clinical decision-making authority, and all financial structures are transparent and visible from day one. The clarifications provided are not theoretical; they reflect how RMP operates in practice across all active studies.

Beyond supporting clinical research operations, RMP is structured to ensure full control over data integrity, regulatory compliance, and execution quality across the entire study lifecycle. RMP strictly adheres to ALCOA principles, ensuring that all data is Attributable, Legible, Contemporaneous, Original, and Accurate. This is enforced through real-time oversight via integrated CTMS, EDC, and EMR access, continuous operational monitoring on-site and remotely, pre-visit internal quality reviews, and aligned SOP frameworks across RMP and all affiliated sites. From study start-up through close-out, these processes ensure full traceability of all study activities, immediate visibility into site performance, consistent adherence to protocol and regulatory standards, and audit-ready operations at all times. RMP does not rely on reactive quality control. It operates under a controlled, real-time execution model that ensures compliance is maintained, not corrected after the fact.

Still have questions?

We would be glad to discuss this in more detail and align directly. Please let us know a convenient time to schedule a call.

                                            Email: admin@rmpsmo.com